TY - JOUR
T1 - Nasal proportional assist ventilation unloads the inspiratory muscles of stable patients with hypercapnia due to COPD
AU - Polese, G.
AU - Vitacca, M.
AU - Bianchi, L.
AU - Rossi, A.
AU - Ambrosino, N.
PY - 2000
Y1 - 2000
N2 - This study was undertaken to assess the physiological effects of proportional assist ventilation (PAV), administered noninvasively through a nose mask, on ventilatory pattern, arterial blood gases, lung mechanics, and inspiratory muscle effort in stable, hypercapnic patients with chronic obstructive pulmonary disease. In 15 patients, PAV was set by adjusting volume assist (VA) and flow assist (FA) according to the 'run-away' technique and the patient's comfort respectively. The level of support was fixed at 80% of the total possible assistance and averaged 13.9±4.1 cmH2O·L-1 and 4.1±1.3 cmH2O·L-1σ for VA and FA, respectively. Continuous positive airway pressure (CPAP) was established at 2 cmH2O and then increased to 5 cmH2O. Physiological measurements were made during spontaneous breathing (SB), after more than 40 min of PAV, and 20 min after the rise in CPAP. On average, PAV improved ventilation (10.3±2.1 to 12.5±2.0 L·m-1), tidal volume (0.60±0.11 to 0.76±0.24 L), arterial oxygen tension and arterial carbon dioxide pressure (from 6.7±0.7 to 7.1±0.9 and from 7.6±1.0 to 7.2±1.2 kPa, respectively). During SB, pulmonary resistance and dynamic lung elastance averaged 15.0±7.6 cmH2O·L-1·s and 15.8±8.0 cmH2O·L-1, respectively. Assuming a normal chest wall elastance (5 cmH2O·L-1), VA and FA relieved respectively ~70% of the elastic and 30% of the resistive burden, with PAV set with the procedure of this study. The overall magnitude of the patients' inspiratory effort, measured by means of the oesophageal and diaphragmatic pressure time product in 10 patients was significantly reduced by PAV, on average, 328±122 to 226±118 (-31%) and 361±119 to 254±126 (-30%) cmH2O · min-1, respectively. In 10 patients the electrical activity of the diaphragm (Edi) was also reduced by PAV to ~70%, on average, of the SB activity. The rise of CPAP 2-5 cmH2O did not cause any further significant change in the physiological variables. In all instances there was a good patient-ventilator interaction, the ventilatory breath never entering into the patient's neural expiratory time. These data show that nasal proportional assist ventilation can provide physiological benefits to the stable hypercapnic chronic obstructive pulmonary disease patients. In fact, proportional assist ventilation, which was well tolerated by all patients, unloaded the inspiratory muscles and improved arterial blood gases. Further studies can clarify whether these beneficial physiological effects of nasal proportional assist ventilation can bear profitable consequences in the overall clinical management of chronic obstructive pulmonary disease patients with chronic carbon dioxide retention. (C) ERS Journals Ltd 2000.
AB - This study was undertaken to assess the physiological effects of proportional assist ventilation (PAV), administered noninvasively through a nose mask, on ventilatory pattern, arterial blood gases, lung mechanics, and inspiratory muscle effort in stable, hypercapnic patients with chronic obstructive pulmonary disease. In 15 patients, PAV was set by adjusting volume assist (VA) and flow assist (FA) according to the 'run-away' technique and the patient's comfort respectively. The level of support was fixed at 80% of the total possible assistance and averaged 13.9±4.1 cmH2O·L-1 and 4.1±1.3 cmH2O·L-1σ for VA and FA, respectively. Continuous positive airway pressure (CPAP) was established at 2 cmH2O and then increased to 5 cmH2O. Physiological measurements were made during spontaneous breathing (SB), after more than 40 min of PAV, and 20 min after the rise in CPAP. On average, PAV improved ventilation (10.3±2.1 to 12.5±2.0 L·m-1), tidal volume (0.60±0.11 to 0.76±0.24 L), arterial oxygen tension and arterial carbon dioxide pressure (from 6.7±0.7 to 7.1±0.9 and from 7.6±1.0 to 7.2±1.2 kPa, respectively). During SB, pulmonary resistance and dynamic lung elastance averaged 15.0±7.6 cmH2O·L-1·s and 15.8±8.0 cmH2O·L-1, respectively. Assuming a normal chest wall elastance (5 cmH2O·L-1), VA and FA relieved respectively ~70% of the elastic and 30% of the resistive burden, with PAV set with the procedure of this study. The overall magnitude of the patients' inspiratory effort, measured by means of the oesophageal and diaphragmatic pressure time product in 10 patients was significantly reduced by PAV, on average, 328±122 to 226±118 (-31%) and 361±119 to 254±126 (-30%) cmH2O · min-1, respectively. In 10 patients the electrical activity of the diaphragm (Edi) was also reduced by PAV to ~70%, on average, of the SB activity. The rise of CPAP 2-5 cmH2O did not cause any further significant change in the physiological variables. In all instances there was a good patient-ventilator interaction, the ventilatory breath never entering into the patient's neural expiratory time. These data show that nasal proportional assist ventilation can provide physiological benefits to the stable hypercapnic chronic obstructive pulmonary disease patients. In fact, proportional assist ventilation, which was well tolerated by all patients, unloaded the inspiratory muscles and improved arterial blood gases. Further studies can clarify whether these beneficial physiological effects of nasal proportional assist ventilation can bear profitable consequences in the overall clinical management of chronic obstructive pulmonary disease patients with chronic carbon dioxide retention. (C) ERS Journals Ltd 2000.
KW - Chronic obstructive
KW - Chronic respiratory failure
KW - Mechanical ventilation
KW - Proportional assist ventilation
KW - Pulmonary disease
KW - Respiratory muscles
UR - http://www.scopus.com/inward/record.url?scp=0033796906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033796906&partnerID=8YFLogxK
U2 - 10.1034/j.1399-3003.2000.016003491.x
DO - 10.1034/j.1399-3003.2000.016003491.x
M3 - Article
C2 - 11028666
AN - SCOPUS:0033796906
VL - 16
SP - 491
EP - 498
JO - European Journal of Respiratory Diseases
JF - European Journal of Respiratory Diseases
SN - 0903-1936
IS - 3
ER -